[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fapi-pet\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fapi-pet":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100599051","phase-2-comparing-18f-fapi-pet-guided-abdominal-radiotherapy-combined-with-second-line-standard-therapy-and-cadonilimab-versus-second-line-standard-therapy-in-colorectal-cancer-with-peritoneal-metastasis-100599051",false,"NCT07079462","Comparing 18F-FAPI PET-Guided Abdominal Radiotherapy Combined With Second-Line Standard Therapy and Cadonilimab Versus Second-Line Standard Therapy in Colorectal Cancer With Peritoneal Metastasis","A Prospective Randomized Controlled Study Comparing 18F-FAPI PET-Guided Abdominal Radiotherapy Combined With Second-Line Standard Therapy and Cadonilimab Versus Second-Line Standard Therapy in Colorectal Cancer With Peritoneal Metastasis","Inclusion Criteria:\n\n* 1\\. Age of 18 years or older. 2. Peritoneal metastasis of colorectal cancer confirmed by histological or cytological examination (International Union Against Cancer 8th edition of colorectal cancer staging).\n\n  3\\. Progression after receiving standard first-line treatment before enrollment; but excluding any type of immunotherapy.\n\n  4\\. Eastern Cooperative Oncology Group (ECOG) score of 0-1, with an expected survival time of more than 6 months.\n\n  5\\. ECOG score of 0-1. 6. Expected survival time of ≥ 24 weeks. 7. Laboratory tests for bone marrow, liver and kidney organ functions and coagulation function within 7 days before the first administration were in compliance with the study requirements (no blood transfusion, blood products, use of granulocyte colony-stimulating factor or other hematopoietic stimulating factors for correction within 7 days before the laboratory tests).\n\n  8\\. Women with reproductive capacity must have a negative blood pregnancy test result within 7 days before the first administration. Male or female patients with reproductive capacity voluntarily use effective contraceptive methods during the study period and within 6 months after the last study medication, such as double barrier contraceptive methods, condoms, oral or injectable contraceptive drugs, intrauterine devices, abstinence, etc. All female patients will be considered to have reproductive capacity, unless the female patient has naturally menopause, artificial menopause or sterilization (uterus removal, bilateral ovary removal).\n\n  9\\. Voluntary enrollment and signing of informed consent form, following the trial treatment plan and visit schedule.\n\nExclusion Criteria:\n\n* 1\\. Absolute neutrophil count (ANC) \\\u003C 1.5 × 109\u002FL, or platelet count \\\u003C 100 × 109\u002FL (for patients with liver metastasis, platelet count \\\u003C 80 × 109\u002FL), or hemoglobin \\\u003C 9 g\u002FdL; blood transfusion within 2 weeks prior to enrollment is not allowed to meet the inclusion criteria.\n\n  2\\. Serum total bilirubin \\> 1.5 times the upper limit of normal (ULN); for patients with liver metastasis, \\> 2.5 times ULN.\n\n  3\\. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\> 2.5 times ULN, or for patients with liver metastasis, ALT and\u002For AST \\> 5 times ULN.\n\n  4\\. Serum creatinine \\> 1.5 times ULN, or creatinine clearance rate \\\u003C 50 ml\u002Fmin (calculated according to the Cockcroft-Gault formula).\n\n  5\\. Partial thromboplastin time (APTT) or prothrombin time (PT) \\> 1.5 times ULN (based on the normal values of the clinical trial center).\n\n  6\\. The researcher determines clinically significant severe electrolyte abnormalities.\n\n  7\\. Urine protein test of 2+ or above, or 24-hour urine protein quantification ≥ 1.0 g\u002F24h.\n\n  8\\. Hypertension that is not well controlled by medication, defined as: systolic blood pressure \\> 140 mmHg or diastolic blood pressure \\> 90 mmHg.\n\n  9\\. The patient currently has active peptic ulcer, ulcerative colitis, or other digestive tract diseases or active bleeding from an unresected tumor, or the researcher determines that it may cause gastrointestinal bleeding or perforation; or if there was a previous gastrointestinal perforation or gastrointestinal fistula, and the patient has not recovered after surgical treatment.\n\n  10\\. Within 6 months before enrollment, there is a history of arterial thrombosis or deep vein thrombosis, or within 2 months before enrollment, there is evidence or history of bleeding tendency or history of bleeding, regardless of severity.\n\n  11\\. Within 12 months before enrollment, a stroke event or transient ischemic attack occurred.\n\n  12\\. Within 6 months before enrollment, heart disease including congestive heart failure, acute myocardial infarction, severe\u002Funstable angina pectoris or coronary artery bypass surgery; or NYHA class 2 or above heart dysfunction patients; left ventricular ejection fraction (LVEF) \\\u003C 50%.\n\n  13\\. Uncontrolled malignant pleural effusion, ascites or pericardial effusion (defined as not being effectively controlled by diuretics or puncture as determined by the researcher).\n\n  14\\. Any patient who has received any anti-PD-1 antibody, anti-PD-L1 antibody, anti-PD-L2 antibody or anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) antibody (or any other antibody acting on the T cell co-stimulation or checkpoint pathways) before enrollment.\n\n  15\\. Within 4 weeks before enrollment, received any form of radiotherapy. 16. At the screening stage, there is a clinically detectable second primary malignant tumor, or other malignant tumors occurred in the past 5 years, excluding fully treated non-melanoma skin cancer, cervical carcinoma in situ and superficial bladder tumor \\[non-invasive tumors, carcinoma in situ and T1 (tumor invasion of the lamina propria)\\], if present.\n\n  17\\. Known clinical significance of liver disease history, including but not limited to known hepatitis B virus (HBV) infection and positive HBV DNA (≥ 1 × 104\u002Fml); known hepatitis C virus (HCV) infection and positive HCV RNA (≥ 1 × 103\u002Fml), or liver cirrhosis, etc.\n\n  18\\. Pregnant or lactating women or women with a possibility of pregnancy who have a positive pregnancy test before the first medication; or female participants who are unwilling to implement strict contraception during the study.\n\nThe researcher considers that the subject has any clinical or laboratory abnormalities or non-compliance issues that make them unsuitable to participate in this clinical study.","ALL","18 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Main objective:\n\n1\\. To compare the objective response rate (ORR) of 18F-FAPI PET-guided abdominal region radiotherapy combined with second-line standard treatment versus cabozantinib and second-line standard treatment in the treatment of peritoneal metastasis of colorectal cancer.\n\nSecondary objectives:\n\n1. To compare the disease control rate (DCR), duration of continuous remission (DoR), progression-free survival (PFS) and overall survival (OS) of 18F-FAPI PET-guided abdominal region radiotherapy combined with second-line standard treatment versus cabozantinib and second-line standard treatment in the treatment of peritoneal metastasis of colorectal cancer.\n2. To evaluate the safety and tolerability of 18F-FAPI PET-guided abdominal region radiotherapy combined with second-line standard treatment versus cabozantinib.",[26,27,28],"Colorectal Cancer","Peritoneal (Metastatic) Cancer","FAPI PET","RECRUITING","2026-06-30",{"date":32,"type":33},"2026-07-02","ACTUAL",{"date":35,"type":33},"2024-08-07",{"date":37,"type":20},"2028-01-31",{"name":39,"class":40},"Fudan University","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100636282","fapi-petct-imaging-in-arrhythmogenic-right-ventricular-cardiomyopathy-arvc-fapi-arvc-100636282","NCT07563660","FAPI PET\u002FCT Imaging in Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) (FAPI-ARVC))","Incremental Diagnostic and Prognostic Value of 68Ga-DOTA-SA-FAPI PET\u002FCT Imaging in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)","FAPI-ARVC","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Established diagnosis of arrhythmogenic right ventricular cardiomyopathy according to the 2010 Revised Task Force Criteria and\u002For the Padua criteria\n* Under active follow-up at the study center\n* Ability to understand the study procedures and provide written informed consent\n\nExclusion Criteria:\n\n* History of malignancy\n* Severe renal impairment\n* Severe hepatic impairment\n* Pregnancy or breastfeeding\n* Prior 68Ga-DOTA-SA-FAPI PET\u002FCT imaging\n* Inability or unwillingness to provide written informed consent\n* Any medical, clinical, or logistical condition that, in the opinion of the investigators, could interfere with study participation, image interpretation, or completion of follow-up",{"count":50,"type":20},15,[52],"NA","Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited heart muscle disease associated with fibrofatty myocardial replacement, ventricular arrhythmias, and an increased risk of sudden cardiac death. Although current diagnostic approaches, including the 2010 Task Force Criteria and the Padua criteria, improve recognition of the disease, early diagnosis remains challenging, particularly when structural abnormalities are subtle or absent on conventional imaging. Echocardiography and cardiac magnetic resonance imaging are central to evaluation, but their sensitivity for early or active fibrotic remodeling may be limited. This limitation may be particularly relevant in patients who are unable to undergo cardiac magnetic resonance imaging, in whom 68Ga-DOTA-SA-FAPI PET\u002FCT may provide complementary diagnostic information.\n\nThis prospective single-group diagnostic imaging study aims to investigate the incremental value of protocol-specified 68Ga-DOTA-SA-FAPI PET\u002FCT imaging in patients with ARVC. FAPI PET\u002FCT is a novel molecular imaging method that targets activated fibroblasts and may allow non-invasive detection of active myocardial fibrosis.Fifteen adult patients with an established diagnosis of ARVC will undergo protocol-specified 68Ga-DOTA-SA-FAPI PET\u002FCT imaging in addition to clinical evaluation, electrocardiography, echocardiography, and review of previously obtained cardiac magnetic resonance imaging findings. FAPI PET\u002FCT findings will be compared with conventional diagnostic criteria and other clinical and imaging parameters, including previously available cardiac magnetic resonance imaging findings. Participants will also be followed clinically for 6 months after imaging to explore possible associations between FAPI uptake and short-term clinical outcomes, including arrhythmic events, ventricular function, and laboratory markers.\n\nThe study is expected to provide preliminary evidence on whether 68Ga-DOTA-SA-FAPI PET\u002FCT may improve the detection of myocardial fibrosis and contribute to diagnostic assessment and risk stratification in ARVC. It may also help clarify the potential role of FAPI PET\u002FCT in patients who are unable to undergo cardiac magnetic resonance imaging. The findings may support future larger prospective studies in this field.",[55,28,56],"Arrhythmogenic Right Ventricular Cardiomyopathy","Cardiac Magnetic Resonance Imaging",[55,58,59,60,61,62,56,63],"Fibroblast Activation Protein","Positron Emission Tomography Computed Tomography","Molecular Cardiac Imaging","Sudden Cardiac Death Risk Stratification","Inherited Cardiomyopathy","Myocardial Fibrosis","2026-04-30",{"date":66,"type":33},"2026-05-04",{"date":68,"type":33},"2025-04-16",{"date":70,"type":20},"2026-10-26",{"name":72,"class":40},"Istanbul University - Cerrahpasa",1]